Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 7/20 | 0.60 |
| ▸ | RAB9A | P51151 | 7/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.50 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.50 |
| ▸ | RELA | Q04206 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 4/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.49 |
| ▸ | BRAF | P15056 | 6/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | STAT1 | P42224 | 1/20 | 0.48 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 1/20 | 0.46 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25162487 | 0.86 | KDM4E (0.63) | NPC1RAB9AKDM4ESMN1; SMN2LMNA | |
| SCHEMBL4794157 | 0.85 | KDM4E (0.61) | NPC1RAB9AKDM4ESMN1; SMN2LMNA | |
| SCHEMBL26622020 | 0.84 | KDM4E (0.67) | NPC1RAB9AKDM4ESMN1; SMN2LMNA | |
| SCHEMBL20435602 | 0.83 | NPC1 (0.59) | NPC1RAB9AKDM4ESMN1; SMN2LMNA | |
| SCHEMBL11351081 | 0.80 | BRAF (0.58) | NPC1RAB9AKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL11472378 | 0.80 | MAP2K1 (0.65) | NPC1RAB9AKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL31682544 | 0.80 | NPC1 (0.49) | NPC1RAB9AKDM4ESMN1; SMN2LMNA | |
| SCHEMBL3161762 | 0.79 | BRAF (0.58) | NPC1RAB9AKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL3161975 | 0.79 | MARK2 (0.62) | NPC1RAB9AKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL13778074 | 0.78 | KDM4E (0.55) | NPC1RAB9AKDM4ESMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170145011-A1 | Pyrrolopyrazine-Spirocyclic piperidine amides as modulators of ion channels | VERTEX PHARMA (US) | 2017-05-25 | — | — | US | disclosed |
| US-9511067-B2 | Substituted spiro[piperidine-4,1'-pyrrolo[1,2-a]pyrazine]s as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-12-06 | — | — | US | disclosed |
| EP-3056495-A1 | PYRROLOPYRAZINE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | Vertex Pharmaceuticals Inc. (US) | 2016-08-17 | — | — | EP | disclosed |
| EP-2670752-B1 | PYRROLOPYRAZINE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMA (US) | 2016-03-16 | — | — | EP | disclosed |
| US-20150174127-A1 | Pyrrolopyrazine-Spirocyclic piperidine amides as modulators of ion channels | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2015-06-25 | — | — | US | disclosed |
| US-8916565-B2 | Pyrrolopyrazine-spirocyclic piperidine amides as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-12-23 | — | — | US | disclosed |
| EP-2670752-A1 | PYRROLOPYRAZINE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | Vertex Pharmaceuticals Incorporated (US) | 2013-12-11 | — | — | EP | disclosed |
| WO-2012106499-A1 | PYRROLOPYRAZINE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-08-09 | — | — | WO | disclosed |
| US-20120196869-A1 | PYRROLOPYRAZINE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2012-08-02 | — | — | US | disclosed |
| US-20080058351-A1 | Deuterated pyrazolo(1,5-a)pyrimidine compounds; sedative or hypnotic agents; sleep disorders such as insomnia; modulating a GABA receptor-chloride ionophore complex in a cell through binding to the neurosteroid site on the complex | CONCERT PHARMACEUTICALS INC. (US) | 2008-03-06 | — | — | US | disclosed |
| US-20080058351-A1 | Deuterated pyrazolo(1,5-a)pyrimidine compounds; sedative or hypnotic agents; sleep disorders such as insomnia; modulating a GABA receptor-chloride ionophore complex in a cell through binding to the neurosteroid site on the complex | CONCERT PHARMACEUTICALS INC. (US) | 2008-03-06 | — | — | US | disclosed |
| WO-2008005471-A2 | NOVEL HETEROBICYCLIC COMPOUNDS | CONCERT PHARMACEUTICALS INC. (US) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150174127-A1 | Pyrrolopyrazine-Spirocyclic piperidine amides as modulators of ion channels | KCNJ2, KCNJ5, KCNJ1 | NPC1 692/4885RAB9A 2212/4885KDM4E 2838/4885 |
| US-20170145011-A1 | Pyrrolopyrazine-Spirocyclic piperidine amides as modulators of ion channels | KCNJ2, KCNJ5, KCNJ1 | NPC1 692/4885RAB9A 2212/4885KDM4E 2838/4885 |
| US-20080058351-A1 | Deuterated pyrazolo(1,5-a)pyrimidine compounds; sedative or hypnotic agents; sleep disorders such as insomnia; modulating a GABA receptor-chloride ionophore complex in a cell through binding to the neurosteroid site on the complex | GABRA5, GABRA1, GABRA4 | NPC1 367/4885RAB9A 3290/4885KDM4E 2844/4885 |
| US-20120196869-A1 | PYRROLOPYRAZINE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | KCNJ2, KCNJ5, KCNJ1 | NPC1 692/4885RAB9A 2212/4885KDM4E 2838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.